SF-36 questionnaire was administered to patients who received COS with follitropin alfa (n = 22) or follitropin beta (n = 21) in a randomized controlled clinical study. SF-36 scores before and after COS were obtained for each patient. Results for the eight “dimensions” of the SF-36 were projected using multivariate analysis to produce a composite QOL score. Statistical tests were performed to determine the percentage of relevant information captured by the multivariate analysis and hence the quality of the composite score. The bootstrap technique was used to generate additional random samples. The Kolmogorov–Smirnov test was used to compare the distributions of the composite scores for the follitropin alfa and beta groups. RESULTS: The test performed to validate the composite QOL score gave a value of 0.55 (55% of relevant information captured), compared with an expected score of 0.125 for a random projection of eight dimensions into one. The distribution of composite scores for the two groups was significantly different after 30 simulations (p = 0.004), suggesting a difference in the effects of the two treatments on QOL. A graphical plot of the results of 5000 simulations showed that the follitropin beta group had a greater reduction in QOL as a result of COS compared with the follitropin alfa group. CONCLUSIONS: Mathematical modeling confirms a statistically significant difference in QOL effects of the two treatments on QOL.

PATIENT AND PARTNER TREATMENT SATISFACTION SCALE (TSS) IN ERECTILE DYSFUNCTION
Kubin M1, Britt D2, Trudeau E2, Fugl-Meyer A3, Gondek K4
1Bayer AG, Wuppertal, Germany; 2Bayer Pharmaceutical, West Haven, CT, USA; 3MAPI Values, Lyon, France; 4Upsala University, Upsala, Sweden; 5Bayer Pharmaceutical Corporation, West Haven, CT, USA

OBJECTIVE: To develop an instrument to assess male patient’s and their female partner’s satisfaction with the treatment for erectile dysfunction (ED) and assess the comprehensiveness, comprehension, acceptability and clarity of the instrument. METHODS: Four phases were performed in the questionnaire development; item generation, face and content validity, cognitive debriefing, cultural and language adaptation. Item generation was based on literature review, hypothesized characteristics of the drug and in-depth interviews with patients and their partners. Perceptions and feelings related to the condition and their expectations of treatment were examined. Items were generated simultaneously in English, French, and German and adapted to each culture. Content and face validity were assessed by interviews with patients and partners in 5 countries. Testing of structure and response scales, cognitive debriefing and verifiability of conceptual equivalence between languages was assessed. RESULTS: A total of 55 interviews were conducted to test face and content validity for patients, partners and experts. The final content areas deemed important included spontaneity, quality of erection, quality of ejaculation, sexual pleasure, satisfaction with orgasm, confidence, reliability of treatment, side effect, convenience, overall satisfaction, conformity to treatment expectations and intentions for continued use of drug. Cognitive debriefing with patients and partners found no problems with comprehension. Results of the debriefing found some words to be problematic. There were no cultural differences found between the English, French, or German version. The questionnaire was revised at each phase. The final questionnaire for both the patient and the partner contained 19 questions. The questionnaire was then translated into 14 additional languages for use in clinical trials. CONCLUSIONS: The TSS is a comprehensive measure of male ED patients and their respective partners. Further work is needed to validate the TSS, identify the domains, test the responsiveness and determine the appropriate scoring.

A NEW INSTRUMENT TO MEASURE THE PSYCHOLOGICAL IMPACT OF ERECTILE DYSFUNCTION. VALIDATION OF A SPANISH VERSION OF THE JOHNSON AND MCCOY’S SELF-CONFIDENCE SCALE
Martin-Morales A1, Manero M2, Regadera L1, Artés M3
1Hospital Carlos Haya, Málaga, Spain; 2Q.F. Bayer, Barcelona, Spain; 3GlaxoSmithKline, Madrid, Spain; 4Adelphi Tangis S.L., Barcelona, Spain

Erectile dysfunction has an impact on Health Related Quality of Life. It can be expected that it also has some impact on psychological well-being-related variables, such as self-confidence and self-esteem. It is, therefore, worthwhile making available in different languages validated versions of instruments able to measure these parameters. OBJECTIVE: To perform the linguistic and psychometric validation of a cultural adaptation to Spanish of the Johnson and McCoy’s Self-Confidence Scale to be used in patients with erectile dysfunction (ED). METHODS: After conducting a linguistic validation of the scale through two forward translations, backward translation, and cognitive debriefing interviews the final reconciled version of the scale was to be administered to 200 male patients with ED and 200 male subjects without ED. Participants were screened for ED by general practitioners and further reviewed by urologists. In addition to the self-confidence scale, all participants were asked to answer the Rosenberg’s self-esteem scale. RESULTS: A total of 387 subjects completed the self-confidence questionnaire. It showed a high internal consistency (Cronbach’s alpha = 0.82), similar to the original English version (Cronbach’s alpha = 0.84). All items showed a high correlation with the scale. The correlation of the scale with self-esteem score was adequate (r = 0.60). A factorial structure of 3 dimensions was observed in the Spanish version of the self-confidence scale comparable to the original structure. Self-confidence scores were
shown to be significantly lower in ED patients than in non-ED subjects (84.4 vs. 89.4, respectively; \( p = 0.0109 \)), suggesting an association between self-confidence and erectile dysfunction. CONCLUSION: Assessment of self-confidence through this Spanish version of the Johnson and McCoy's questionnaire is reliable and valid and provides a new instrument to measure the psychological impact of erectile dysfunction.

**PWH8**

**DEVELOPMENT AND INITIAL TESTING OF A NEW PATIENT-REPORTED QUESTIONNAIRE—ERECTION QUALITY SCALE**

Wincze JP, Fehnel SE, McLeod LD, Granger AL, Merchant S

1Brown University, Providence, RI, USA; 2RTI-Health Solutions, Research Triangle Park, NC, USA; 3Bayer Pharmaceuticals Corporation, West Haven, CT, USA

OBJECTIVE: There are currently no available psychometric instruments that measure erection quality. A quantitative measure of erectile quality has potential value as a measure in both clinical research and in the clinical treatment of erectile dysfunction. The objective of this study is to describe the development and evaluation of a new patient-reported questionnaire, designed to measure changes in erection quality. METHODS: Based on input from interviews with men across the United States and recommendations from an expert panel, seven constructs were selected for inclusion in the questionnaire. Multiple items were drafted to measure each of the key constructs, which included various question wordings, formats, and response category options. An iterative process of cognitive testing, item revision, and item reduction led to the identification of fifteen items and their optimal response scales. At the completion of the cognitive testing, the psychometric properties of the questionnaire were evaluated as part of a 200-subject test-retest study. Participants were classified into ED-Untreated, ED-Treated, and Normal Sexual Functioning groups in order to gather information about how well the items differentiated among men with different levels of erectile functioning. RESULTS: The psychometric evaluation demonstrated no floor or ceiling effects. The study results supported a strong one-factor structure, indicating that the EQS should be reported using one overall score. Internal consistency is supported with Cronbach alpha values of 0.94 and 0.95 (for visit 1 and 2, respectively). An intraclass correlation coefficient of 0.79 denotes adequate test-retest reliability. Furthermore, the EQS showed promise for differentiating patients from the three classifications, ED-Untreated, ED-Treated, and Normal Sexual Functioning, a preliminary indication of discriminate validity. CONCLUSIONS: The results of the development and initial evaluation of the EQS are favorable and provide evidence of the questionnaire’s utility for measuring erection quality. A future study is planned to demonstrate the instrument’s responsiveness.